Segment Reporting (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2026 USD ($) numberOfSegments	Mar. 31, 2025 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | numberOfSegments	1
Segment Reporting Information [Line Items]
Revenues	$ 179,126	$ 1,764
General and administrative	5,889	5,832
Restructuring costs	0	12,373
Net Income (Loss)	169,695	(24,526)
Adjustments and reconciling items	0	0
Reportable Segment
Segment Reporting Information [Line Items]
Revenues	179,126	1,764
Imdusiran IM-PROVE I, II & III clinical trials expense	891	2,171
AB-101-001 Phase 1a/1b clinical trial expense	526	1,899
Other early research and development programs expense	2,703	4,889
General and administrative	5,889	5,832
Restructuring costs	0	12,373
Other segment expense	237	323
Interest income	815	1,197
Net Income (Loss)	$ 169,695	$ (24,526)
Consolidated net loss	169,695	(24,526)